China License Out

Announced Date: 2024-11-14 (November 14, 2024) Asset Name: LM-299 Licensor: LaNova Medicines Ltd. (LaNova) (China) Licensee … [China BD 2024] LaNova and MSD Enters a 3.3 billion USD License on PD-1/VEGF BsAbs LM-299Read more

Announced Date: 2024-11-12 (November 12, 2024) Asset Name: HEC88473 (APL-18881) Licensor: Sunshine Lake Pharma (member of … [China BD 2024] Sunshine Lake (HEC) and Apollo  enters a 938 million USD License on FGF21/GLP-1 Bi-specific Fusion Protein HEC88473 (APL-18881)Read more

Announced Date: 2024-9-30 (September 30, 2024) Asset Name: RGT-419B(GDC-4198) and RGT-587(GDC-0587) Licensor: Regor Pharmaceuticals (China) Licensee (Buyer): … [China BD 2024] Regor and Genentech (Roche) enters a license on two CDK inhibitor programsRead more

Announced Date: 2024-10-16 (October 16, 2024) Asset Name: Undisclosed Licensor (Seller): Chengdu Baiyu Pharmaceutical  (China) Licensee … [China BD 2024] Chengdu Baiyu and Novartis enters a 1.17 billion USD license on small molecule anti-tumor assetRead more

Announced Date: 2024-10-29 (October 29, 2024) Asset Name: CMG1A46 Licensor: Chimagen Biosciences  (China) Licensee (Buyer): GSK … [China BD 2024] Chimagen and GSK enters a 850 billion USD acquisition on CD19xCD20 targeted TCE CMG1A46Read more

Announced Date: 2024-08-07 (August 7, 2024) Asset Name: CN201  Licensor: Curon (Curon Biopharmaceutical , China) Licensee (Buyer): … [China BD 2024] Curon and MSD enters a 1.3 billion USD transaction for CD3xCD19-targeting TCE BiAbs CN201 Read more

Announced Date: 2024-08-01 (August 1, 2024) Asset Name: IMM2510 and IMM27M Licensor: ImmuneOnco Biopharmaceuticals (Shanghai) (China) … [China BD 2024] ImmuneOnco and Instil Bio Enters a 2.05 billion USD License on two mAb Assets, PD-L1xVEGF Bispecific Antibody IMM2510 and Anti-CTLA-4 Antibody IMM27MRead more

Announced Date: 2024-06-14 (June 14, 2024) Asset Name: Olverembatinib Licensor: Ascentage Pharma (China)  Licensee (Buyer): Takeda … [China BD 2024] Ascentage and Takeda enters an Option License on BCR-ABL TKI OlverembatinibRead more

Announced Date: 2024-06-13 ( June 13, 2024) Asset Name: FG-M701 Licensor: FutureGen Biopharmaceutical (Beijing) (China) Licensee (Buyer): AbbVie … [China BD 2024] FutureGen and AbbVie enters a 1.71 billion USD license on TL1A antibody FG-M701Read more